Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology • Bone Marrow Transplant • Aplastic Anemia • Bone Marrow Failure • Pediatric Hematology
For pediatric severe aplastic anemia, is an alemtuzumab (campath) based conditioning regimen preferred over ATG?
What patient factors may influence the choice of one over the other
What are the specific benefits/risks (ie in terms of GVHD, graft failure, etc)